Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimers Disease Neurology Module
Host: James Galvin, MD, MPH, FANA
\n\n Guest: Jon Toledo, MD, PhD
\n\n\n \n
Recently, Alzheimer\u2019s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (A\u03b2) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this program employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity focuses on the role of neurology clinicians including when to raise clinical suspicion of ARIA in the clinic, how to evaluate suspected ARIA, and what courses of action may be needed to treat/manage ARIA should it occur.
Note that the core activity is supplemented by an interactive clinical summary \u2026